论文部分内容阅读
目的:研究血清IL-6及IL-12水平在骨肉瘤患者与健康体检者之间的差异及临床意义。方法:采用酶联免疫吸附法(ELISA)检测160例骨肉瘤患者及250例健康体检者的外周血血清IL-6及IL-12水平,比较两组间IL-6、IL-12水平的差异及其相关性,探讨血清IL-6及IL-12水平与骨肉瘤发病及进展的关系。结果:骨肉瘤组患者血清IL-6水平明显高于对照组(P<0.01),IL-12水平明显低于对照组(P<0.01)。在骨肉瘤患者中,处于肿瘤发病Ⅲ~Ⅳ期的患者其血清IL-12水平低于Ⅰ~Ⅱ期患者(P<0.05);合并远处转移的患者血清IL-12水平低于不发生远处转移的患者(P<0.05)。血清IL-6水平与IL-12水平无明显线性相关(P>0.05)。结论:血清IL-6及IL-12水平在骨肉瘤患者表达异常,两者在骨肉瘤的发生中可能起免疫调节作用,IL-12的低表达可能与骨肉瘤的进展相关。
Objective: To study the difference and clinical significance of serum IL-6 and IL-12 levels between patients with osteosarcoma and healthy subjects. Methods: Serum levels of IL-6 and IL-12 in peripheral blood of 160 osteosarcoma patients and 250 healthy controls were detected by enzyme-linked immunosorbent assay (ELISA). The differences of IL-6 and IL-12 levels between the two groups were compared And its correlation, explore the relationship between serum IL-6 and IL-12 levels and the incidence and progress of osteosarcoma. Results: The level of serum IL-6 in osteosarcoma group was significantly higher than that in control group (P <0.01). The level of IL-12 in osteosarcoma group was significantly lower than that in control group (P <0.01). In patients with osteosarcoma, the level of serum IL-12 in stage Ⅲ ~ Ⅳ tumor patients was lower than that in stage Ⅰ ~ Ⅱ patients (P <0.05). The serum level of IL-12 in patients with distant metastasis was lower than that in patients without distant tumor (P <0.05). There was no significant linear correlation between serum IL-6 level and IL-12 level (P> 0.05). CONCLUSIONS: Serum levels of IL-6 and IL-12 are abnormally expressed in osteosarcoma patients, both of which may play an immunomodulatory role in the development of osteosarcoma. The low expression of IL-12 may be related to the progress of osteosarcoma.